FDA-cleared profile

ScanDiags Ortho L-Spine MR-Q

ScanDiags AG · MRI · FDA-cleared (510(k))

Authorized purpose: Semi-automatic lumbar MRI segmentation and area and distance measurements with radiologist-approved PDF report to PACS; adjunct only.

Clinical role
Segmentation and measurement aid that produces a report for radiologist approval; it is not intended to make a diagnosis.
Images and patients
MRI · Spine
Key limitation
Keep in mind: The exact labeling excludes pregnancy, contrast examinations, postoperative complications and infection, and states that the software does not diagnose disease; it is intended as an adjunct to professional review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Semi-automatic lumbar MRI segmentation and area and distance measurements with radiologist-approved PDF report to PACS; adjunct only.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Spine Input: DICOM lumbar spine MR studies from adults, without the excluded contrast, pregnancy, postoperative-complication or infection scenarios described in the labeling.
  • Who uses it?Intended users: Radiologists and other trained healthcare professionals reviewing lumbar MRI examinations.
  • What does the software produce?Output: Segmentations and area or distance measurements for vertebral bodies, discs, neuroforamina and thecal sac, with a PDF report containing overlays sent to PACS.
  • What is its most important limitation?Key limitation: The exact labeling excludes pregnancy, contrast examinations, postoperative complications and infection, and states that the software does not diagnose disease; it is intended as an adjunct to professional review.

Clinical takeaway. Clinical role: Semi-automatic lumbar MRI segmentation and area and distance measurements with radiologist-approved PDF report to PACS; adjunct only.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary describes two validation cohorts, including 100 studies for segmentation and a separate 101-study, seven-site measurement cohort; reported agreement included vertebral-body area ICC 0.95 and vertebral-body Dice similarity coefficient 0.95.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Semi-automatic lumbar MRI segmentation and area and distance measurements with radiologist-approved PDF report to PACS; adjunct only.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Segmentation and measurement aid that produces a report for radiologist approval; it is not intended to make a diagnosis.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
DICOM lumbar spine MR studies from adults, without the excluded contrast, pregnancy, postoperative-complication or infection scenarios described in the labeling.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Segmentations and area or distance measurements for vertebral bodies, discs, neuroforamina and thecal sac, with a PDF report containing overlays sent to PACS.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult lumbar MRI interpretation and reporting workflows.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Radiologists and other trained healthcare professionals reviewing lumbar MRI examinations.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The exact labeling excludes pregnancy, contrast examinations, postoperative complications and infection, and states that the software does not diagnose disease; it is intended as an adjunct to professional review.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
The FDA summary describes two validation cohorts, including 100 studies for segmentation and a separate 101-study, seven-site measurement cohort; reported agreement included vertebral-body area ICC 0.95 and vertebral-body Dice similarity coefficient 0.95.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary describes two validation cohorts, including 100 studies for segmentation and a separate 101-study, seven-site measurement cohort; reported agreement included vertebral-body area ICC 0.95 and vertebral-body Dice similarity coefficient 0.95.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Vertebral-body area intraclass correlation

0.95 ICC

  • EndpointAutomated versus radiologist vertebral-body area
  • PopulationLumbar MR segmentation cohort of 100 studies
  • Tested versionScanDiags Ortho L-Spine MR-Q release reviewed in K242607

Vertebral-body segmentation Dice similarity coefficient

0.95 Dice

  • EndpointAutomated versus radiologist vertebral-body segmentation
  • PopulationLumbar MR segmentation cohort of 100 studies
  • Tested versionScanDiags Ortho L-Spine MR-Q release reviewed in K242607

Neuroforamen segmentation Dice similarity coefficient

0.86 Dice

  • EndpointAutomated versus radiologist neuroforamen segmentation
  • PopulationLumbar MR segmentation cohort of 100 studies
  • Tested versionScanDiags Ortho L-Spine MR-Q release reviewed in K242607

Ortho L-Spine MR-Q segmentation validation

  • DesignRetrospective segmentation validation against three U.S. board-certified musculoskeletal radiologists
  • Population100 individual lumbar MR studies from hospital groups in Missouri and North Carolina across GE, Siemens and Philips systems
  • Scopeexact submission
  • Tested versionScanDiags Ortho L-Spine MR-Q release reviewed in K242607
  • Samplen=100
  • IndependenceSponsor or vendor study

K242607 FDA 510(k) summary

The summary reports a second measurement cohort separately; this record is limited to the 100-study segmentation cohort.

Ortho L-Spine MR-Q measurement validation

  • DesignRetrospective multi-site measurement validation against radiologist reference
  • Population101 lumbar MR studies across seven U.S. sites and multiple MRI manufacturers
  • Scopeexact submission
  • Tested versionScanDiags Ortho L-Spine MR-Q release reviewed in K242607
  • Samplen=101
  • Sites7
  • IndependenceSponsor or vendor study

K242607 FDA 510(k) summary measurement cohort

The exact FDA summary describes the measurement cohort separately from the 100-study segmentation cohort.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM lumbar spine MR studies from adults, without the excluded contrast, pregnancy, postoperative-complication or infection scenarios described in the labeling.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for ScanDiags Ortho L-Spine MR-Q, K242607

  2. Routing

    Source context, not route validation: The exact submission describes a PDF report with overlays sent to PACS. The company-issued ImagoPlus family release describes standardized reports and integration into radiology operations, but it predates the exact clearance and is not treated as a current K242607 interface specification.

    Scope: Product family.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · ScanDiags accelerates commercialization of the ImagoPlus medical imaging AI platform

  3. AI processing

    Source context, not route validation: The reviewed FDA materials describe processing lumbar MR studies and returning a PDF report with overlays to PACS; current hosting and site architecture were not established.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for ScanDiags Ortho L-Spine MR-Q, K242607

  4. Returned objects

    Source context, not route validation: Segmentations and area or distance measurements for vertebral bodies, discs, neuroforamina and thecal sac, with a PDF report containing overlays sent to PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for ScanDiags Ortho L-Spine MR-Q, K242607

  5. Viewer/worklist/report

    Unresolved route: Segmentations and area or distance measurements for vertebral bodies, discs, neuroforamina and thecal sac, with a PDF report containing overlays sent to PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for ScanDiags Ortho L-Spine MR-Q, K242607

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The reviewed FDA materials describe processing lumbar MR studies and returning a PDF report with overlays to PACS; current hosting and site architecture were not established.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
The exact submission describes a PDF report with overlays sent to PACS. The company-issued ImagoPlus family release describes standardized reports and integration into radiology operations, but it predates the exact clearance and is not treated as a current K242607 interface specification.
  • Product family
  • Checked 2026-09-07

PACS report delivery

The exact labeling describes a PDF report with overlays sent to PACS for radiologist approval.

exact submission · checked 2026-09-06

Family MRI hardware and operations context

The company-issued ImagoPlus release describes compatibility across MRI hardware and integration into radiology operations; it is family-level and predates the exact clearance.

product family · checked 2026-09-07

Human approval boundary

The exact product is an adjunct: the radiologist reviews the segmentations, measurements and report rather than delegating diagnosis to the software.

exact submission · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242607
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor press release, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No numeric price was published in the reviewed sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "ScanDiags reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    Current security scope, attestations and contract terms were not established; FDA labeling statements are preserved separately.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. K242607 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ScanDiags Ortho L-Spine MR-Q model card (K242607)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision record and summary reviewed for ScanDiags Ortho L-Spine MR-Q, K242607

    U.S. Food and Drug Administration - Published 2025-02-21 - Accessed 2026-09-06

    Scope: identity, intended_use, performance, limitations, implementation, cybersecurity_labeling

  8. ScanDiags accelerates commercialization of the ImagoPlus medical imaging AI platform

    ScanDiags Health Technologies Inc. (company-issued release via Newsfile) - Published 2024-02-05 - Accessed 2026-09-07

    Scope: product_family, clinical_workflow, reporting, MRI_integration

Research history

  1. K242607 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K220497

CoLumbo

Smart Soft Healthcare AD

Authorized purpose: CoLumbo is an image post-processing and measurement software tool that provides quantitative spine measurements from previously-acquired DICOM lumbar spine Magnetic Resonance (MR) images for users' review, analysis, and interpretation. It provides the following functionality to assist users in visualizing, measuring and documenting out-of range measurements:- Feature segmentation;- Feature measurement;- Threshold-based labeling of out-of-range measurement; and- Export of measurement results to a written report for user's review, revise and approval. Columbo does not produce or recommend any type of medical diagnosis or treatment. Instead, it simply helps users to more easily identify and classify features in lumbar MR images and compile a report. The user is responsible forconfirming/modifying settings, reviewing and verifying the software-generated measurements, inspecting out-of-range measurements, and approving draft report content using their medical judgment and discretion. The device is intended to be used only by hospitals and other medical institutions. Only DICOM images of MRI acquired from lumbar spine exams of patients aged 18 and above are considered to be valid input. CoLumbo does not support DICOM images of patients that are pregnant, undergo MRI scan with contrast media, or have post-operational complications, scoliosis, tumors, infections, fractures.

Modality
MRI
Anatomy
Spine
Decision
2022-06-23
FDA-cleared K241329

SubtleSYNTH (1.x)

Subtle Medical, Inc.

Authorized purpose: SubtleSYNTH is a software medical device consisting of a machine-learning algorithm that synthesizes a SynthSTIR contrast image from T1-weighted and T2-weighted spine MR images.

Modality
MRI
Anatomy
Spine
Decision
2024-07-11
FDA-cleared K233030

BoneMRI

MRIguidance B.V

MRI-processing software that creates an added bone-contrast image series for review beside the original scan.

Modality
MRI
Anatomy
Spine
Decision
2024-03-01
FDA-cleared K230197

BoneMRI v1.6

MRIguidance B.V.

Authorized purpose: MRI-based BoneMRI v1.6 image enhancement for visualizing pelvic and L3-S1 lumbar bone structures with enhanced contrast; not for tumor diagnosis or monitoring and not a CT replacement.

Modality
MRI
Anatomy
Spine
Decision
2023-02-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history